Product Description
Rimonabant puehu video
Raw Rimonabant pauda mau huapalapala
| Name: | ʻO ka pauka Rimonabant (SR141716) |
| CAS: | 168273-06-1 |
| Nā Kaulike Molecular: | C22H21Cl3N4O |
| Molecular Weight: | 463.8 |
| Wahi Manaʻo: | 230 ° C - 240 ° C |
| Hōʻoia Kōkua: | Pauka -20°C 3 makahiki |
| kala like 'ole: | pauda hina-keʻokeʻo |
Rimonabant Background
Hoʻomaka ka mōʻaukala o Rimonabant i ka hopena o 1990s a me ka 2000 mua i ka wā i hoʻomaka ai nā mea noiʻi e noiʻi i ka ʻōnaehana endocannabinoid a me kāna mau hopena i nā kaʻina physiological like ʻole, me ka hoʻoponopono ʻana i ka makemake a me ke kaulike o ka ikehu.
I loko o kēia manawa, ua ʻike nā kānaka ʻepekema i nā mea hoʻokipa cannabinoid i loko o ke kino, i kapa ʻia ʻo CB1 receptors, ka mea i loaʻa nui i ka lolo a me nā ʻiʻo peripheral. He kuleana ko kēia mau mea loaʻa i ka hoʻololi ʻana i ka makemake, ka ʻai ʻana i ka meaʻai, a me ka hoʻolilo ʻana i ka ikehu.
Hoʻoikaika ʻia e ka ulu ʻana o ka ʻike e pili ana i ke komo ʻana o ka ʻōnaehana endocannabinoid i ka mālama ʻana i ka ʻai, ua hoʻomaka nā hui lāʻau lapaʻau i ka hoʻomohala ʻana i nā antagonists koho CB1 e hoʻopaʻa i ka momona a me nā kūlana pili.
I ka makahiki 1999, ua hoʻomaka ka hui lāʻau lapaʻau Farani ʻo Sanofi-Synthélabo (i kēia manawa ʻo Sanofi) e hoʻomohala i kahi lāʻau i kapa ʻia ʻo Rimonabant. Ua hoʻolālā ʻia ʻo Rimonabant e hoʻopaʻa i nā mea loaʻa CB1, me ka pale ʻana i ka hana o ka ʻōnaehana endocannabinoid.
Ua mālama ʻia nā hoʻokolohua lapaʻau e loiloi i ka pono a me ka palekana o Rimonabant i ka mālama ʻana i ka momona a me nā maʻi metabolic pili. Ua hōʻike ʻia nā haʻawina i nā hopena hoʻohiki, e hōʻike ana i ka pohō kaumaha a me ka hoʻomaikaʻi ʻana i nā mea pilikia cardiovascular, e like me ke kiʻekiʻe o ka cholesterol a me ka pale ʻana o ka insulin.
Ma muli o nā hopena maikaʻi mai kēia mau ho'āʻo ʻana, ua loaʻa iā Rimonabant ka ʻae kānāwai ma 2006 ma ka European Union ma lalo o ka inoa kālepa Acomplia. ʻO ia ka lāʻau lapaʻau mua i kūkulu pono ʻia no ka mālama ʻana i ka momona i loko o hoʻokahi mau makahiki.
Eia naʻe, ʻoiai kona kūleʻa mua, ua kū ʻo Rimonabant i nā pilikia a me nā hoʻopaʻapaʻa. ʻO nā hōʻike o nā hopena ʻaoʻao psychiatric, me ke kaumaha, ka hopohopo, a me ka manaʻo suicidal, i puka mai i ka wā o ka nānā ʻana ma hope o ka mākeke. ʻO ka hopohopo no kēia mau hopena maikaʻi ʻole i alakaʻi ʻia i ka haʻalele ʻana o Rimonabant mai ka mākeke ma kekahi mau ʻāina, me ka European Union ma 2008.
ʻO ka haʻalele ʻana o Rimonabant i hōʻike i ke koʻikoʻi o ka nānā pono ʻana i ka palekana a me nā pilikia psychiatric e pili ana i nā lāʻau lapaʻau e kuhikuhi ana i ka ʻōnaehana endocannabinoid. ʻOiai ʻaʻole i hoʻokō ʻo Rimonabant i kāna ʻōlelo mua ma ke ʻano he lāʻau anti-obesity, ua hāʻawi ʻo ia i nā ʻike koʻikoʻi i ka pilina paʻakikī ma waena o ka ʻōnaehana endocannabinoid a me ka hoʻoponopono metabolic.
Mai ka haʻalele ʻana o Rimonabant, ua hoʻomau nā hana noiʻi e ʻimi i ka hiki ke hoʻopaʻa i ka ʻōnaehana endocannabinoid, akā me ka manaʻo nui i ka hoʻomohala ʻana i nā pūhui e hoʻēmi i nā pilikia psychiatric e pili ana me CB1 receptor blockade.
Pauda Rimonabant
ʻO Rimonabant Powder kahi lāʻau lapaʻau i loaʻa ka nānā no kona hoʻohana pono ʻana i ka lāʻau lapaʻau. Aia ia i kahi papa o nā lāʻau i kapa ʻia ʻo selective cannabinoid receptor antagonists. Ua hoʻokumu mua ʻia ʻo Rimonabant ma ke ʻano he lāʻau anti-obesity, e kuhikuhi ana i ka ʻōnaehana endocannabinoid e kōkua i ka hoʻoponopono ʻana i ka makemake a me ke kaumaha.
Hiki i ka Powder form o Rimonabant ke maʻalahi i ka lawelawe ʻana a me ka hoʻopuehu ʻana i nā kaʻina hana. Hiki ke hoʻoheheʻe ʻia ʻo Rimonabant Powder i ka wai, ʻo ia hoʻi he palena liʻiliʻi i ka hoʻonā wai. Eia naʻe, hiki iā ia ke hōʻike i ka hoʻoheheʻe ʻoi aku ka maikaʻi i nā mea hoʻoheheʻe organik e like me ka ethanol, methanol, a i ʻole propylene glycol. ʻO nā hiʻohiʻona solubility o Rimonabant he mea nui e noʻonoʻo i ka wā o ka hoʻomohala ʻana.
ʻO ke ʻano hana o Rimonabant
ʻO ka hana o ka hana a Rimonabant e pili ana i kāna pilina me ka ʻōnaehana endocannabinoid i ke kino. ʻO Rimonabant kahi antagonist receptor cannabinoid koho, e kuhikuhi ana i nā mea hoʻokipa CB1 i loaʻa i ka lolo a me nā ʻiʻo peripheral.
Ke hoʻokomo ʻia, hoʻopaʻa ʻia ʻo Rimonabant a hoʻopaʻa i nā mea loaʻa CB1, e pale ana i ka hoʻāla ʻana o kēia mau mea loaʻa e nā cannabinoids endogenous e like me anandamide. Ma ka pale ʻana i nā mea hoʻokipa CB1, hoʻololi ʻo Rimonabant i ka hana o ka ʻōnaehana endocannabinoid, kahi hana i nā kaʻina physiological like ʻole, me ka hoʻoponopono ʻana i ka makemake, ke kaulike o ka ikehu, a me ka lipid metabolism.
ʻO ka mea kikoʻī, ʻo ka blockade o CB1 receptors e Rimonabant e pili ana i kēia:
Mana Manaʻo Appetite
Hoʻokomo ʻia nā mea loaʻa CB1 i ka hoʻoponopono ʻana i ka makemake a me ka ʻai ʻana i ka meaʻai. Ke ho'ālaʻia nā mea hoʻokipa CB1, hoʻoulu lākou i ka hoʻokuʻuʻana i nā neuropeptides e hoʻoulu ai i ka pōloli a hoʻonui i ka waiwai o ka meaʻai. ʻO ka hoʻopaʻa ʻana o Rimonabant i nā mea hoʻokipa CB1 e hōʻemi i ka hana o ka ʻōnaehana endocannabinoid, e alakaʻi ana i ka emi ʻana o ka makemake a me ka hoʻemi ʻana i ka ʻai.
Hoolilo Imi
Hoʻopili ka ʻōnaehana endocannabinoid i ka lilo o ka ikehu ma o ka hoʻoponopono ʻana i ka thermogenesis, ke kaʻina hana e hana ai ke kino i ka wela a puhi i nā calorie. Ma ke kāohi ʻana i nā mea loaʻa CB1, hiki iā Rimonabant ke hoʻonui i ka hoʻonui ʻana i ka ikehu, e hāʻawi ana i ka pohō kaumaha.
Lipid Metabolism
Hoʻopili ʻia ka hoʻāla ʻana o CB1 me ka hoʻonui ʻana i ka lipogenesis (waihona momona) a me ka lipolysis i hoʻemi ʻia (faʻihaʻi momona). Hiki i ka Rimonabant's antagonism o CB1 receptors ke hoʻopau i ka lipogenesis a me ka hoʻoikaika ʻana i ka lipolysis, hiki ke alakaʻi i ka emi ʻana o ka hōʻiliʻili momona o ke kino.
He mea nui ia e hoʻomaopopo ʻoiai ʻo Rimonabant e hana nui ma ke ʻano he antagonist receptor CB1, hiki ke hōʻike i kekahi mau hopena hou a i ʻole ka launa pū ʻana me nā mea loaʻa a i ʻole nā pūnaewele i loko o ke kino. Hiki ke ʻokoʻa nā ʻano hana a me nā hopena o Rimonabant a aia nō ke kumuhana o ka noiʻi hoʻomau.
ʻO keʻano o ka hana o Rimonabant Powder e like me ka Rimonabant ma kona mauʻano'ē aʻe. ʻO Rimonabant Powder e pili ana i ka Powdered form o ka lāʻau Rimonabant, kahi mea koho cannabinoid receptor antagonist.
Ke lawelawe ʻia ʻo Rimonabant Powder, ma ka waha a i ʻole ma o ka hoʻopili ʻana i nā ʻano like ʻole, e hoʻoheheʻe ʻia a komo i loko o ke kino. Ke hoʻopili ʻia, pili ia me ka ʻōnaehana endocannabinoid ma ka huli ʻana i nā mea hoʻokipa CB1 i loaʻa i loko o ka lolo a me nā ʻiʻo peripheral.
He aha nā hopena o Rimonabant?
ʻO Rimonabant, kahi lāʻau anti-obesity, i hoʻokumu mua ʻia e kōkua i nā poʻe e hakakā nei me ka mālama kaumaha. ʻO kāna pōmaikaʻi nui, ʻo ia ka hiki ke hoʻopau i ka ʻai a hoʻoikaika i ka pohō kaumaha. ʻO ka mea kikoʻī, ua manaʻo ʻia ʻo Rimonabant e hoʻohana ʻia no kēia mau kumu:
Pākuʻi Kaomi
Ua hoʻolālā ʻia ʻo Rimonabant e hōʻemi i ka ʻai a hoʻoikaika i ka pohō kaumaha ma ke kāohi ʻana i nā mea loaʻa CB1 i loko o ka lolo e pili ana i ka hoʻoponopono ʻai. Ma ke kāohi ʻana i kēia mau mea hoʻokipa, manaʻo ʻo Rimonabant e hoʻemi i ka manaʻo o ka pōloli a me ka makemake, e kōkua ana i nā poʻe e hoʻomalu i kā lākou ʻai.
Weight Loss
Ma muli o ka hoʻopau ʻana i ka ʻai, ua manaʻo ʻia ʻo Rimonabant e alakaʻi i ka pohō kaumaha i nā poʻe me ka momona a i ʻole ke kaumaha. Ua hōʻike ʻia nā hoʻokolohua lapaʻau e hiki i ka mālama ʻana iā Rimonabant ke hoʻemi nui i ke kaumaha ke hui pū ʻia me ka ʻai a me ka hoʻoikaika kino.
Hoʻomaikaʻi Metabolic
Ua hōʻike ʻo Rimonabant i nā pono kūpono i ka hoʻomaikaʻi ʻana i nā ʻāpana metabolic e pili ana i ka momona, e like me ka lipid profiles, insulin resistance, a me nā hōʻailona o ka pilikia cardiovascular. Manaʻo ia e hoʻolaha i nā loli maikaʻi i kēia mau mea metabolic, i hoʻohālikelike pinepine ʻia i nā poʻe me ke kaumaha keu.
Kokua Hooki Puhi
Ua noiʻi ʻia ʻo Rimonabant no kona hoʻohana ʻana i mea kōkua i ka hoʻopau ʻana i ka uahi. Ua manaʻo ʻia ma ke kāohi ʻana i nā mea loaʻa CB1, hiki iā Rimonabant ke hōʻemi i ka makemake nicotine a me nā hōʻailona hoʻihoʻi, e kākoʻo ana i nā poʻe i kā lākou hoʻoikaika ʻana e haʻalele i ka puhi paka.
No ke aha ke kumu o Rimonabant i ke kaumaha?
ʻAʻole maopopo i nā ʻano hana pololei e hiki ai iā Rimonabant ke alakaʻi i ke kaumaha. Eia naʻe, ua hōʻike ʻia nā haʻawina a me nā hōʻike lapaʻau i kahi pilina ma waena o ka hoʻohana ʻana iā Rimonabant a me ka piʻi nui ʻana o ke kaumaha a me nā hopena psychiatric ʻē aʻe.
ʻO Rimonabant, ma ke ʻano he cannabinoid receptor antagonist koho, poloka i ka hana o nā mea loaʻa CB1 i ka ʻōnaehana endocannabinoid. Hoʻokani nā mea hoʻokipa CB1 i nā ʻano hana physiological like ʻole, me ka hoʻoponopono ʻana i ke ʻano a me ka hoʻoponopono ʻana i ka naʻau. Ma ka pale ʻana i nā mea loaʻa CB1, hiki i Rimonabant ke hoʻopau i ka hana maʻamau o ka ʻōnaehana endocannabinoid, hiki ke kōkua i nā loli i ke ʻano a me ka maikaʻi o ka noʻonoʻo.
Hoʻohui ʻia, pili ka ʻōnaehana endocannabinoid i ka hoʻoponopono ʻana i nā pane koʻikoʻi a me ka modulation o nā neurotransmitters e like me serotonin, ka mea i ʻike ʻia he kuleana koʻikoʻi i ka hoʻoponopono ʻana i ke ʻano. ʻO ka hoʻopau ʻana i kēia mau kaʻina hana ma o CB1 receptor antagonism hiki ke alakaʻi i nā hōʻailona depressive.
He mea nui e hoʻomaopopo i nā pane o kēlā me kēia kanaka i nā lāʻau lapaʻau hiki ke ʻokoʻa, a ʻaʻole nā mea a pau e lawe iā Rimonabant e ʻike i ke kaumaha a i ʻole nā hopena pili. Eia nō naʻe, ʻo ka loaʻa ʻana o ke kaumaha a me nā hōʻailona psychiatric ʻē aʻe e pili ana i ka hoʻohana ʻana iā Rimonabant i alakaʻi i ka haʻalele ʻana o ka lāʻau mai ka mākeke ma kekahi mau ʻāina. No laila i kēia manawa ʻaʻole hiki ke maʻalahi ke kūʻai ʻana iā Rimonabant Powder ma ka lāʻau lapaʻau kūloko. Inā makemakeʻoe e kūʻai i ka Rimonabant Powder ma ka pūnaewele,ʻoiai he nui nā mea kūʻai Rimonabant Powder, ponoʻoe e koho i ka mea hilinaʻi.
Inā hopohopo ʻoe e pili ana i ke kaumaha a i ʻole nā pilikia e pili ana i ke olakino noʻonoʻo, he mea koʻikoʻi ke kamaʻilio me ke kauka olakino no ka loiloi kūpono a me ke alakaʻi.
ʻO ka wehe ʻana o Rimonabant a me ka noiʻi mau
Ma muli o nā hopohopo palekana, ʻoi aku ka nui o nā hopena psychiatric, ua hoʻihoʻi ʻia ʻo Rimonabant mai ka mākeke ma kekahi mau ʻāina. Eia naʻe, ke hoʻomau nei ka noiʻi a me ka hoʻomohala ʻana i nā lāʻau lapaʻau e pili ana i ka ʻōnaehana endocannabinoid, me ka nānā ʻana i ka hoʻomohala ʻana i nā pūhui ʻē aʻe a me nā lāʻau lapaʻau e pili ana i nā palena o Rimonabant.
Hiki i ka noiʻi e hiki mai ana ke hoʻomaʻemaʻe i ka ʻike o ka ʻōnaehana endocannabinoid, e ʻimi ana i nā noi kūpono o ka modulation endocannabinoid i nā ʻano olakino like ʻole, a me ka hoʻomohala ʻana i nā lāʻau lapaʻau palekana a ʻoi aku ka maikaʻi ma kēia kahua.
Ma hea e kūʻai ai i ka pauka Rimonabant?
He mea nui ia e hoʻomaopopo ʻoiai he nui nā Rimonabant Powder no ke kūʻai aku ma ka pūnaewele. ʻAʻole hiki ke loaʻa no ke kūʻai a hoʻohana ʻana. Hoʻohana nui ʻia ʻo Rimonabant Powder i ka noiʻi a me ka hoʻomohala ʻana, me nā hui lāʻau lapaʻau a me nā laboratories, no ke kumu o ke aʻo ʻana i nā waiwai o ka lāʻau lapaʻau, ke alakaʻi ʻana i nā hoʻokolohua preclinical a me ka hoʻomohala ʻana i nā huahana lāʻau hou. Ma muli o nā hopohopo palekana a me nā hopena hopena, he mea nui e kūʻai i ka Rimonabant Powder kiʻekiʻe e pale i nā hopena kūpono ʻole. Pehea e koho ai i kahi mea hana Rimonabant hilinaʻi, pono ʻoe e nānā i kā lākou HPLC kūʻokoʻa a me COA hōʻike. Hāʻawi mākou i ka maikaʻi Rimonabant Powder. No nā kauoha kūʻai nui o Rimonabant Powder, e loaʻa iā ʻoe kahi kumukūʻai hoʻokūkū loa.
Rimonabant Powder Testing Report-HNMR
He aha ka HNMR a he aha ka HNMR spectrum e haʻi iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā huila i loaʻa nā pūhui i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Pehea e kūʻai ai i ka pauka Rimonabant mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu WhatsApp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) iā ʻoe i loko o 12 mau hola.
❷E hāʻawi iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala lawe, a me ka lā i manaʻo ʻia e hiki mai ai (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Shira Hirsch
ʻO ka Obesity a me ka Metabolism Laboratory, POB 12065, Ierusalema 9112001, ʻIseraʻela
2. Dalal AlKhelb
Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA
3. Robert Ettaro
'Oihana o Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA
4. Alessandra Porcu
'Oihana o Biomedical Sciences, University of Cagliari, 09042, Monserrato, Italia
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
E hoʻomaopopo '
[1] Soyka M. "Rimonabant and depression."Pharmacopsychiatry.2008 Sep;41(5):204-5.doi: 10.1055/s-2008-1078744.Epub 2008 Sep 1.PMID: 18763226
[2] Boyd ST, Fremming BA. Ann Pharmacother.1 Apr;2005(39):4-684.doi: 90/aph.10.1345E1.Epub 499 Mar 2005.PMID: 8
[3] Curioni C,André C.”Rimonabant no ke kaumaha nui a me ka momona.”Cochrane Database Syst Rev.2006 Oct 18;2006(4):CD006162.doi: 10.1002/14651858.CD006162.pub2.PMID: 17054276
[4] Wierzbicki AS.”Rimonabant: endocannabinoid inhibition for the metabolic syndrome.”Int J Clin Pract.2006 Dec;60(12):1697-706.doi: 10.1111/j.1742-1241.2006.01210.x.17109677PMXNUMX.
[5] Cox SL. "Rimonabant hydrochloride: he mea noiʻi no ka mālama ʻana i nā mea pilikia cardiovascular."Drugs Today (Barc).2005 Aug;41(8):499-508.doi: 10.1358/dot.2005.41.8.893709. PMID: 16234873
[6] Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. "Rimonabant: he lāʻau antiobesity wale nō? ʻO nā hōʻike o kēia manawa ma kāna hopena pleiotropic.
